Overview
| 别名 | Coagulation factor VIII; Antihemophilic factor; AHF; Procoagulant component) [Cleaved into: Factor VIIIa heavy chain; 200 kDa isoform; Factor VIIIa heavy chain; 92 kDa isoform; Factor VIII B chain; Factor VIIIa light chain] |
| 基因名 | F8 |
| UniProt ID | P00451 |
| 反应种属 | Human |
| 应用 | IHC-P |
| 宿主 | Mouse |
| 偶联物 | Unconjugated |
| 修饰 | Unmodified |
| 亚型 | IgG2a |
| 克隆号 | 2Y2-D2-X3 |
| 克隆性 | Monoclonal Antibody |
| 分子量 | Calculated MW: 267 kDa |
| 纯化方式 | Affinity Purified |
| 产品形式 | Liquid |
| 推荐稀释比 | IHC-1:200 |
| 存储缓冲液 | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% sodium azide |
| 保存温度 | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 背景信息 | Coagulation factor VIII (FVIII) is a crucial protein in the blood clotting process. It is produced primarily in the liver and circulates in the bloodstream bound to von Willebrand factor. When activated, FVIII acts as a cofactor for factor IX, catalyzing the activation of factor X and ultimately leading to fibrin clot formation. Mutations in the F8 gene, which encodes FVIII, can result in hemophilia A, the most common form of this bleeding disorder. Over 1,300 different mutations have been identified, ranging from single base pair changes to large inversions. These mutations can lead to reduced FVIII production or abnormal protein function, impairing the blood clotting process and causing excessive bleeding. Conversely, elevated FVIII levels have been associated with increased risk of venous thromboembolism and may be an independent risk factor for arterial thrombotic diseases such as myocardial infarction and stroke. |
检测原理